share_log

Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $78

Benzinga ·  Jul 31 20:33  · Ratings

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $38 to $78.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment